Cara Therapeutic (CARA)

NASDAQ
Currency in USD
Disclaimer
1.67
-0.05(-2.91%)
Closed
After Hours
1.71+0.04(+2.40%)
Trading near 52-week Low
Day's Range
1.661.73
52 wk Range
1.6612.81
Prev. Close
1.72
Open
1.72
Day's Range
1.66-1.73
52 wk Range
1.66-12.81
Volume
561,341
Average Vol. (3m)
1,105,839
1-Year Change
-81.02%
Shares Outstanding
54,077,681
Analysts
Technical
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
15.43
Upside +823.87%

People Also Watch

6.140
APRN
-1.76%
2.61
ALT
+1.95%
58.24
FTNT
-0.92%
40.76
BWA
+1.65%

Cara Therapeutic Company Profile

Cara Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in the discovery, development, and commercialization of novel therapeutics to treat serious medical conditions, including pruritus. The Company’s KORSUVA (difelikefalin) injection is the first and only FDA-approved treatment for moderate-to-severe pruritus associated with chronic kidney disease (CKD-aP) in adults undergoing hemodialysis (HD). Its novel compound, difelikefalin, is a highly selective, primarily peripherally acting kappa opioid receptor (KOR) agonist. The Company is developing an oral formulation of difelikefalin and has Phase III programs ongoing for the treatment of pruritus in patients with non-dialysis dependent advanced chronic kidney disease (NDD-CKD), and atopic dermatitis (AD). In addition, the Company has initiated a Phase II/III program of oral difelikefalin for the treatment of moderate-to-severe pruritus in patients with notalgia paresthetica (NP).

Employees
106

Income Statement